

Management of hepatocellular carcinoma: Report of Co Annual Meeting of the Japan Society of Hepatology (200

Hepatology Research

40, 667-685

DOI: [10.1111/j.1872-034x.2010.00673.x](https://doi.org/10.1111/j.1872-034x.2010.00673.x)

Citation Report

#	ARTICLE	IF	CITATIONS
1	Real Practice of Hepatocellular Carcinoma in Japan: Conclusions of the Japan Society of Hepatology 2009 Kobe Congress. <i>Oncology</i> , 2010, 78, 180-188.	0.9	46
2	Liver Cancer Working Group Report. <i>Japanese Journal of Clinical Oncology</i> , 2010, 40, i19-i27.	0.6	65
3	Radiofrequency Ablation for Hepatocellular Carcinoma: Updated Review in 2010. <i>Oncology</i> , 2010, 78, 113-124.	0.9	134
4	Positioning of a Molecular-Targeted Agent, Sorafenib, in the Treatment Algorithm for Hepatocellular Carcinoma and Implication of Many Complete Remission Cases in Japan. <i>Oncology</i> , 2010, 78, 154-166.	0.9	89
5	Sorafenib in hepatocellular carcinoma: efficacy and predictive factors. <i>Journal of Medical Colleges of PLA</i> , 2011, 26, 324-334.	0.1	3
6	Radiotherapeutic Strategies in the Management of Hepatocellular Carcinoma. <i>Oncology</i> , 2011, 81, 123-133.	0.9	24
7	Multidisciplinary Management of Nonresectable Hepatocellular Carcinoma. <i>Oncology</i> , 2011, 81, 134-140.	0.9	21
8	Hepatocellular Carcinoma in 2011 and Beyond: From the Pathogenesis to Molecular Targeted Therapy. <i>Oncology</i> , 2011, 81, 1-10.	0.9	23
9	Management of Hepatocellular Carcinoma in Japan: Consensus-Based Clinical Practice Guidelines Proposed by the Japan Society of Hepatology (JSH) 2010 Updated Version. <i>Digestive Diseases</i> , 2011, 29, 339-364.	0.8	726
10	Long-term outcome and hepatocellular carcinoma development in chronic hepatitis B or cirrhosis patients after nucleoside analog treatment with entecavir or lamivudine. <i>Hepatology Research</i> , 2011, 41, 405-416.	1.8	39
11	Molecular characteristics of non-cancerous liver tissue in non-hepatocellular carcinoma. <i>Hepatology Research</i> , 2011, 41, 711-721.	1.8	25
12	High prevalence of hepatitis C virus infection in Airin district, Osaka, Japan: A hospital-based study of 1162 patients. <i>Hepatology Research</i> , 2011, 41, 731-737.	1.8	3
13	Survival of patients with advanced hepatocellular carcinoma: Sorafenib versus other treatments. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2011, 26, 1612-1618.	1.4	28
14	Presentation and outcomes of hepatocellular carcinoma patients at a western centre. <i>Hpb</i> , 2011, 13, 712-722.	0.1	27
15	Outcome after partial hepatectomy for hepatocellular cancer within the Milan criteria. <i>British Journal of Surgery</i> , 2011, 98, 1292-1300.	0.1	97
16	Systematic review and meta-analysis of survival and disease recurrence after radiofrequency ablation for hepatocellular carcinoma. <i>British Journal of Surgery</i> , 2011, 98, 1210-1224.	0.1	242
17	Randomized, Phase II Study Comparing Interferon Combined with Hepatic Arterial Infusion of Fluorouracil plus Cisplatin and Fluorouracil Alone in Patients with Advanced Hepatocellular Carcinoma. <i>Oncology</i> , 2011, 81, 281-290.	0.9	64
18	Adjuvant Therapy after Curative Treatment for Hepatocellular Carcinoma. <i>Oncology</i> , 2011, 81, 50-55.	0.9	43

#	ARTICLE	IF	CITATIONS
19	Radiofrequency Ablation of Hepatocellular Carcinoma: A Literature Review. <i>International Journal of Hepatology</i> , 2011, 2011, 1-9.	0.4	73
20	Future Treatment Option for Hepatocellular Carcinoma: A Focus on Brivanib. <i>Digestive Diseases</i> , 2011, 29, 316-320.	0.8	9
21	Early Decrease in α -Fetoprotein, but Not Des- γ -Carboxy Prothrombin, Predicts Sorafenib Efficacy in Patients with Advanced Hepatocellular Carcinoma. <i>Oncology</i> , 2011, 81, 251-258.	0.9	78
22	Molecular Targeted Therapy for Hepatocellular Carcinoma: Bench to Bedside. <i>Digestive Diseases</i> , 2011, 29, 273-277.	0.8	19
23	Recent Advances in Radiofrequency Ablation for the Management of Hepatocellular Carcinoma. <i>Hepatitis Monthly</i> , 2012, 12, e5945.	0.1	12
24	Transarterial Chemoembolization for Hepatocellular Carcinoma over Three Decades: Current Progress and Perspective. <i>Japanese Journal of Clinical Oncology</i> , 2012, 42, 247-255.	0.6	39
25	Application of Radiotherapeutic Strategies in the BCLC-defined Stages of Hepatocellular Carcinoma. <i>Liver Cancer</i> , 2012, 1, 216-225.	4.2	35
26	A Rare Case of Hepatocellular Carcinoma Accompanied by Metastasis of a Cervical Lymph Node. <i>Internal Medicine</i> , 2012, 51, 381-385.	0.3	11
27	Hepatic arterial infusion chemotherapy for advanced hepatocellular carcinoma according to the Barcelona Clinic Liver Cancer (BCLC) classification. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2012, 27, 1850-1857.	1.4	45
28	Computed Tomography Follow-up for the Detection of Hepatocellular Carcinoma Recurrence after Initial Radiofrequency Ablation: A Single-center Experience. <i>Journal of Vascular and Interventional Radiology</i> , 2012, 23, 1269-1275.	0.2	12
29	The management of hepatocellular carcinoma around the world: a comparison of guidelines from 2001 to 2011. <i>Liver International</i> , 2012, 32, 1053-1063.	1.9	101
30	The changing scenario of hepatocellular carcinoma over the last two decades in Italy. <i>Journal of Hepatology</i> , 2012, 56, 397-405.	1.8	84
31	Phase II study of concurrent transarterial chemoembolization and sorafenib in patients with unresectable hepatocellular carcinoma. <i>Journal of Hepatology</i> , 2012, 56, 1336-1342.	1.8	148
32	Risk of hypervascularization in small hypovascular hepatic nodules showing hypointense in the hepatobiliary phase of gadoxetic acid-enhanced MRI in patients with chronic liver disease. <i>Japanese Journal of Radiology</i> , 2012, 30, 743-751.	1.0	28
33	Current Status of Hepatocellular Carcinoma Treatment in Japan. <i>Clinical Drug Investigation</i> , 2012, 32, 3-13.	1.1	22
34	Hepatic Resection for α -BCLC Stage A α -Hepatocellular Carcinoma. The Prognostic Role of Alpha-Fetoprotein. <i>Annals of Surgical Oncology</i> , 2012, 19, 426-434.	0.7	35
35	Comparative analyses of regulatory T cell subsets in patients with hepatocellular carcinoma: A crucial role of CD25 ⁺ FOXP3 ⁺ T cells. <i>International Journal of Cancer</i> , 2012, 131, 2573-2583.	2.3	20
36	Early evaluation of transcatheter arterial chemoembolization-refractory hepatocellular carcinoma. <i>Journal of Gastroenterology</i> , 2012, 47, 343-346.	2.3	25

#	ARTICLE	IF	CITATIONS
37	Hepatic arterial infusion chemotherapy for advanced hepatocellular carcinoma and future treatments for the poor responders. <i>Hepatology Research</i> , 2012, 42, 340-348.	1.8	29
38	Effect of interferon therapy on first and second recurrence after resection of hepatitis C virus-related hepatocellular carcinoma. <i>Hepatology Research</i> , 2012, 42, 564-573.	1.8	22
39	Hepatocellular carcinoma: Towards personalized medicine. <i>Cancer Science</i> , 2012, 103, 846-850.	1.7	44
40	Severity and timing of progression predict refractoriness to transarterial chemoembolization in hepatocellular carcinoma. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2012, 27, 1051-1056.	1.4	57
41	Clinicopathologic Features and Risk Factors for Extrahepatic Recurrences of Hepatocellular Carcinoma After Curative Resection. <i>World Journal of Surgery</i> , 2012, 36, 136-143.	0.8	35
42	Usefulness of miriplatin as an anticancer agent for transcatheter arterial chemoembolization in patients with unresectable hepatocellular carcinoma. <i>Journal of Gastroenterology</i> , 2012, 47, 179-186.	2.3	14
43	Treatment strategies for hepatocellular carcinoma in Japan. <i>Hepatology Research</i> , 2013, 43, 44-50.	1.8	19
44	Clinical outcome of sorafenib treatment in patients with advanced hepatocellular carcinoma refractory to hepatic arterial infusion chemotherapy. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2013, 28, 1834-1841.	1.4	18
45	The expression of transporter OATP2/OATP8 decreases in undetectable hepatocellular carcinoma by Gd-EOB-MRI in the explanted cirrhotic liver. <i>Hepatology International</i> , 2013, 7, 655-661.	1.9	9
46	Warming Effect on Miriplatin-Lipiodol Suspension as a Chemotherapeutic Agent for Transarterial Chemoembolization for Hepatocellular Carcinoma: Preliminary Clinical Experience. <i>CardioVascular and Interventional Radiology</i> , 2013, 36, 1023-1029.	0.9	17
47	Clinical implication of hypovascular hepatocellular carcinoma studied in 4,474 patients with solitary tumour equal or less than 3Åcm. <i>Liver International</i> , 2013, 33, 762-770.	1.9	52
48	Contrast-enhanced computed tomography and ultrasound-guided liver biopsy to diagnose dysplastic liver nodules in cirrhosis. <i>Digestive and Liver Disease</i> , 2013, 45, 43-49.	0.4	23
49	Antitumor efficacy of transcatheter arterial chemoembolization with warmed miriplatin in hepatocellular carcinoma. <i>Hepatology Research</i> , 2013, 43, 942-949.	1.8	20
50	Warming effect on miriplatin-lipiodol suspension for potential use as a chemotherapeutic agent for transarterial chemoembolization of hepatocellular carcinoma: In vitro study. <i>Hepatology Research</i> , 2013, 43, n/a-n/a.	1.8	12
51	Stereotactic body radiation therapy combined with transcatheter arterial chemoembolization for small hepatocellular carcinoma. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2013, 28, 530-536.	1.4	82
52	Radiofrequency ablation for hepatocellular carcinoma. <i>International Journal of Hyperthermia</i> , 2013, 29, 558-568.	1.1	69
53	Simple method for predicting prognosis following transcatheter arterial chemo-embolization for switching to next therapy for advanced hepatocellular carcinoma without venous invasion or metastasis. <i>Acta Hepatologica Japonica</i> , 2013, 54, 161-163.	0.0	2
54	Targets and Approaches to Control Hepatocellular Carcinoma in Future. , 0, , .		0

#	ARTICLE	IF	CITATIONS
55	Transarterial chemoembolization for hepatocellular carcinoma: A review of techniques. <i>World Journal of Hepatology</i> , 2014, 6, 844.	0.8	59
56	Role of stereotactic body radiation therapy for hepatocellular carcinoma. <i>World Journal of Gastroenterology</i> , 2014, 20, 3100.	1.4	69
57	JSH Consensus-Based Clinical Practice Guidelines for the Management of Hepatocellular Carcinoma: 2014 Update by the Liver Cancer Study Group of Japan. <i>Liver Cancer</i> , 2014, 3, 458-468.	4.2	512
58	Clinicopathology of recurrent hepatocellular carcinomas after radiofrequency ablation treated with salvage surgery. <i>Hepatology Research</i> , 2014, 44, 1062-1071.	1.8	15
59	Serum transferrin as a predictor of prognosis for hepatic arterial infusion chemotherapy in advanced hepatocellular carcinoma. <i>Hepatology Research</i> , 2014, 44, 481-490.	1.8	5
60	Re-evaluating transarterial chemoembolization for the treatment of Hepatocellular Carcinoma: Consensus recommendations and review by an International Expert Panel. <i>Liver International</i> , 2014, 34, 174-183.	1.9	68
61	Long-term outcome of elderly patients (75 years or older) with hepatocellular carcinoma. <i>Hepatology Research</i> , 2014, 44, 975-982.	1.8	9
62	Surgical treatment of extrahepatic recurrence of hepatocellular carcinoma. <i>Langenbeck's Archives of Surgery</i> , 2014, 399, 1057-1064.	0.8	10
63	Comparative evaluation of percutaneous laser and radiofrequency ablation in patients with HCC smaller than 4 cm. <i>Radiologia Medica</i> , 2014, 119, 298-308.	4.7	28
64	High risk of lung metastasis after resection of hepatocellular carcinoma more than 7 cm in diameter. <i>Surgery Today</i> , 2014, 44, 1900-1905.	0.7	27
65	Assessment of treatment outcomes based on tumor marker trends in patients with recurrent hepatocellular carcinoma undergoing trans-catheter arterial chemo-embolization. <i>International Journal of Clinical Oncology</i> , 2014, 19, 871-879.	1.0	21
66	Stereotactic ablative body radiotherapy for previously untreated solitary hepatocellular carcinoma. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2014, 29, 372-379.	1.4	74
67	EpCAM-Targeted Therapy for Human Hepatocellular Carcinoma. <i>Annals of Surgical Oncology</i> , 2014, 21, 1314-1322.	0.7	44
68	Transcatheter arterial chemoembolization for hepatocellular carcinoma: Comparison of the therapeutic efficacies between miriplatin and epirubicin. <i>Hepatology Research</i> , 2014, 44, 1072-1080.	1.8	10
69	Biomarkers for virus-induced hepatocellular carcinoma (HCC). <i>Infection, Genetics and Evolution</i> , 2014, 26, 327-339.	1.0	24
70	Efficacy of iron chelator deferoxamine for hepatic arterial infusion chemotherapy in advanced hepatocellular carcinoma patients refractory to current treatments. <i>Hepatology International</i> , 2014, 8, 492-498.	1.9	10
71	Local effect of stereotactic body radiotherapy for primary and metastatic liver tumors in 130 Japanese patients. <i>Radiation Oncology</i> , 2014, 9, 112.	1.2	38
72	Incidence for progression of hypervascular HCC in hypovascular hepatic nodules showing hyperintensity on gadoxetic acid-enhanced hepatobiliary phase in patients with chronic liver diseases. <i>Japanese Journal of Radiology</i> , 2014, 32, 405-413.	1.0	21

#	ARTICLE	IF	CITATIONS
74	Hepatic Resection as a Safe and Effective Treatment for Hepatocellular Carcinoma Involving a Single Large Tumor, Multiple Tumors, or Macrovascular Invasion. <i>Medicine (United States)</i> , 2015, 94, e396.	0.4	110
75	Hepatocellular carcinoma treatment strategies – a case-based review. <i>Journal of Solid Tumors</i> , 2015, 5, .	0.1	3
76	A New Therapeutic Assessment Score for Advanced Hepatocellular Carcinoma Patients Receiving Hepatic Arterial Infusion Chemotherapy. <i>PLoS ONE</i> , 2015, 10, e0126649.	1.1	21
77	Diagnostic Per-Patient Accuracy of an Abbreviated Hepatobiliary Phase Gadoteric Acid-Enhanced MRI for Hepatocellular Carcinoma Surveillance. <i>American Journal of Roentgenology</i> , 2015, 204, 527-535.	1.0	105
78	The combination of transcatheter arterial chemoembolization and sorafenib is well tolerated and effective in Asian patients with hepatocellular carcinoma: Final results of the START trial. <i>International Journal of Cancer</i> , 2015, 136, 1458-1467.	2.3	109
79	The effects of bisphosphonate zoledronic acid in hepatocellular carcinoma, depending on mevalonate pathway. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2015, 30, 619-627.	1.4	20
80	Survival outcomes after stereotactic body radiotherapy for 79 Japanese patients with hepatocellular carcinoma. <i>Journal of Radiation Research</i> , 2015, 56, 561-567.	0.8	57
81	A Novel Therapeutic Combination Sequentially Targeting Aurora B and Bcl-xL in Hepatocellular Carcinoma. <i>Annals of Surgical Oncology</i> , 2015, 22, 3079-3086.	0.7	8
82	Effects of an oral iron chelator, deferasirox, on advanced hepatocellular carcinoma. <i>World Journal of Gastroenterology</i> , 2016, 22, 8967.	1.4	42
83	Significance of the Signal Intensity of Gadoteric Acid-enhanced MR Imaging for Predicting the Efficacy of Hepatic Arterial Infusion Chemotherapy in Hepatocellular Carcinoma. <i>Magnetic Resonance in Medical Sciences</i> , 2016, 15, 111-120.	1.1	11
84	Neutrophil-to-lymphocyte ratio predicts recurrence after radiofrequency ablation in hepatitis B virus infection. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2016, 31, 1291-1299.	1.4	38
85	Response to chemotherapy improves hepatic reserve for patients with hepatocellular carcinoma and Child-Pugh B cirrhosis. <i>Cancer Science</i> , 2016, 107, 1263-1269.	1.7	22
86	The Clinical Impact of Transcatheter Arterial Chemoembolization (TACE)-Induced c-Met Upregulation on TACE Refractoriness in Hepatocellular Carcinoma. <i>Digestive Diseases and Sciences</i> , 2016, 61, 1572-1581.	1.1	7
87	Salvage resection for recurrent or metastatic hepatocellular carcinoma after percutaneous ablation therapy. <i>International Journal of Surgery</i> , 2016, 36, 68-73.	1.1	1
88	Comparison of hepatocellular carcinoma in Eastern versus Western populations. <i>Cancer</i> , 2016, 122, 3430-3446.	2.0	221
89	Recent Trends in the Management of Hepatocellular Carcinoma with Special Emphasis on Treatment with Regorafenib and Immune Checkpoint Inhibitors. <i>Digestive Diseases</i> , 2016, 34, 714-730.	0.8	7
90	Controversies and evidence of hepatic resection for hepatocellular carcinoma. <i>BBA Clinical</i> , 2016, 6, 125-130.	4.1	16
92	Hyperthermic Oncology from Bench to Bedside. , 2016, , .		5

#	ARTICLE	IF	CITATIONS
93	Effect of perioperative parecoxib sodium on postoperative pain control for transcatheter arterial chemoembolization for inoperable hepatocellular carcinoma: a prospective randomized trial. <i>European Radiology</i> , 2016, 26, 3492-3499.	2.3	29
94	Highly sensitive alpha-fetoprotein, <i>Lens culinaris</i> agglutinin-reactive fraction of alpha-fetoprotein and des-gamma-carboxyprothrombin for hepatocellular carcinoma detection. <i>Hepatology Research</i> , 2016, 46, E130-5.	1.8	52
95	Hepatocellular carcinoma in Japanese patients with nonalcoholic fatty liver disease and alcoholic liver disease: multicenter survey. <i>Journal of Gastroenterology</i> , 2016, 51, 586-596.	2.3	49
96	Effects of in-hospital exercise on liver function, physical ability, and muscle mass during treatment of hepatoma in patients with chronic liver disease. <i>Hepatology Research</i> , 2017, 47, E22-E34.	1.8	54
97	Clinical outcome and prognostic factors in hepatocellular carcinoma patients with bone metastases medicated with zoledronic acid. <i>Hepatology Research</i> , 2017, 47, 1053-1060.	1.8	11
98	Serum monomeric laminin ³² as a novel biomarker for hepatocellular carcinoma. <i>Cancer Science</i> , 2017, 108, 1432-1439.	1.7	21
99	Miscellaneous Indications for Embolization: Indications for Bleeding or for Decreasing Vascularity in Different Vascular Beds. , 2017, , 93-128.		0
100	A multicenter Phase II study of sorafenib in Japanese patients with advanced hepatocellular carcinoma and Child Pugh A and B class. <i>Japanese Journal of Clinical Oncology</i> , 2018, 48, 317-321.	0.6	11
101	Performance of protein induced by vitamin K absence or antagonist-II assessed by chemiluminescence enzyme immunoassay for hepatocellular carcinoma detection: a meta-analysis. <i>Scandinavian Journal of Gastroenterology</i> , 2018, 53, 734-740.	0.6	34
102	Diagnostic per-lesion performance of a simulated gadoxetate disodium-enhanced abbreviated MRI protocol for hepatocellular carcinoma screening. <i>Clinical Radiology</i> , 2018, 73, 485-493.	0.5	63
103	A case of hepatocellular carcinoma with iliac metastasis achieving complete long-term remission by multidisciplinary therapy with radiation therapy, transcatheter arterial chemoembolization, and sorafenib. <i>Acta Hepatologica Japonica</i> , 2018, 59, 117-124.	0.0	0
104	Non-Hypervascular Hypointense Nodules at Gadoteric Acid MRI: Hepatocellular Carcinoma Risk Assessment with Emphasis on the Role of Diffusion-Weighted Imaging. <i>Journal of Gastrointestinal Cancer</i> , 2018, 49, 302-310.	0.6	7
105	Evaluation of the assessment for continuous treatment with hepatic arterial infusion chemotherapy-scoring system in patients with advanced hepatocellular carcinoma. <i>Hepatology Research</i> , 2018, 48, E87-E97.	1.8	12
106	Management consensus guideline for hepatocellular carcinoma: 2016 updated by the Taiwan Liver Cancer Association and the Gastroenterological Society of Taiwan. <i>Journal of the Formosan Medical Association</i> , 2018, 117, 381-403.	0.8	92
107	Effects of in-hospital exercise on sarcopenia in hepatoma patients who underwent transcatheter arterial chemoembolization. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2019, 34, 580-588.	1.4	41
108	A Data Mining-based Prognostic Algorithm for NAFLD-related Hepatoma Patients: A Nationwide Study by the Japan Study Group of NAFLD. <i>Scientific Reports</i> , 2018, 8, 10434.	1.6	32
109	Comparison of hepatic arterial infusion chemotherapy between 5-fluorouracil-based continuous infusion chemotherapy and low-dose cisplatin monotherapy for advanced hepatocellular carcinoma. <i>Hepatology Research</i> , 2018, 48, 1118-1130.	1.8	13
110	Utility of scoring systems combining the product of tumor number and size with liver function for predicting the prognosis of patients with hepatocellular carcinoma after hepatectomy. <i>Oncology Letters</i> , 2019, 18, 3903-3913.	0.8	4

#	ARTICLE	IF	CITATIONS
111	Clinical features of hepatocellular carcinoma in nonalcoholic fatty liver disease patients without advanced fibrosis. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2019, 34, 1626-1632.	1.4	19
112	Effect of body composition on survival benefit of hepatic arterial infusion chemotherapy for advanced hepatocellular carcinoma: A comparison with sorafenib therapy. <i>PLoS ONE</i> , 2019, 14, e0218136.	1.1	15
113	Clinical utility of the Liver Frailty Index for predicting muscle atrophy in chronic liver disease patients with hepatocellular carcinoma. <i>Hepatology Research</i> , 2020, 50, 330-341.	1.8	19
114	Effects of In-Hospital Physical Therapy on Activities of Daily Living in Patients with Hepatocellular Carcinoma. <i>International Journal of Environmental Research and Public Health</i> , 2020, 17, 9098.	1.2	4
115	Microwave ablation versus sorafenib for intermediate-stage Hepatocellular carcinoma with transcatheter arterial chemoembolization refractoriness: a propensity score matching analysis. <i>International Journal of Hyperthermia</i> , 2020, 37, 384-391.	1.1	4
116	Impact of Decorin on the Physical Function and Prognosis of Patients with Hepatocellular Carcinoma. <i>Journal of Clinical Medicine</i> , 2020, 9, 936.	1.0	13
117	Effects of In-Hospital Exercise on Frailty in Patients with Hepatocellular Carcinoma. <i>Cancers</i> , 2021, 13, 194.	1.7	15
118	Hepatic Resection for Hepatocellular Carcinoma in Nonalcoholic Fatty Liver Disease. <i>Annals of Surgery Open</i> , 2021, 2, e065.	0.7	10
119	Rethinking the Barcelona clinic liver cancer guidelines: Intermediate stage and Child-Pugh B patients are suitable for surgery?. <i>World Journal of Gastroenterology</i> , 2021, 27, 2784-2794.	1.4	11
120	Efficacy and Safety of Transarterial Chemoembolization in Elderly Patients of Advanced Hepatocellular Carcinoma With Portal Vein Tumor Thrombus: A Retrospective Study. <i>Frontiers in Oncology</i> , 2021, 11, 646410.	1.3	6
121	Arterial chemoembolisation with cisplatin versus epirubicin for hepatocellular carcinoma (ACE 500) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 373-382.	1.3	9
122	Quality Assessment of Clinical Practice Guidelines on the Treatment of Hepatocellular Carcinoma or Metastatic Liver Cancer. <i>PLoS ONE</i> , 2014, 9, e103939.	1.1	17
123	The Efficacy of Continued Sorafenib Treatment after Radiologic Confirmation of Progressive Disease in Patients with Advanced Hepatocellular Carcinoma. <i>PLoS ONE</i> , 2016, 11, e0146456.	1.1	12
124	Profiles Associated with Sarcopenia in Hepatoma Patients Underwent Transcatheter Arterial Chemoembolization: A Data-Mining Analysis. <i>JCSM Clinical Reports</i> , 2018, 3, .	0.5	4
125	A case of hepatocellular carcinoma obtained marked anti-tumor effect by low dose sorafenib after the progression of the disease during high-dose of sorafenib. <i>Acta Hepatologica Japonica</i> , 2012, 53, 564-569.	0.0	3
126	A synchronous hepatocellular carcinoma and renal cell carcinoma treated with radio-frequency ablation. <i>Clinical and Molecular Hepatology</i> , 2014, 20, 306.	4.5	5
127	Hyperglycemia is a significant prognostic factor of hepatocellular carcinoma after curative therapy. <i>World Journal of Gastroenterology</i> , 2013, 19, 249.	1.4	44
128	Chemotherapy for advanced hepatocellular carcinoma in the sorafenib age. <i>World Journal of Gastroenterology</i> , 2014, 20, 4151.	1.4	27

#	ARTICLE	IF	CITATIONS
129	Comparison of percutaneous radiofrequency ablation and CyberKnife [®] for initial solitary hepatocellular carcinoma: A pilot study. <i>World Journal of Gastroenterology</i> , 2015, 21, 13490.	1.4	39
130	Serum SCCA-IgM as a predictor of hepatocellular carcinoma in patients with liver cirrhosis. <i>Open Journal of Gastroenterology</i> , 2012, 02, 56-61.	0.1	14
131	High burden of hepatocellular carcinoma and viral hepatitis in Southern and Central Vietnam: Experience of a large tertiary referral center, 2010 to 2016. <i>World Journal of Hepatology</i> , 2018, 10, 116-123.	0.8	13
132	Advanced hepatocellular carcinoma responds to MK615, a compound extract from the Japanese apricot <i>Prunus mume</i> . <i>World Journal of Hepatology</i> , 2013, 5, 596.	0.8	11
133	Effect of Transarterial Immunoembolization as Preoperative Treatment for Hepatocellular Carcinoma. <i>Annals of Cancer Research and Therapy</i> , 2011, 19, 26-33.	0.1	6
134	Hypermethylation of Suppressor of Cytokine Signaling 1 in Hepatocellular Carcinoma Patients. <i>Asian Pacific Journal of Cancer Prevention</i> , 2012, 13, 3489-3493.	0.5	12
135	Current epidemiology in hepatocellular carcinoma. <i>Expert Review of Gastroenterology and Hepatology</i> , 2021, 15, 1295-1307.	1.4	107
136	Successful treatment against lymphnode metastasis by endoscopic ultrasonography-guided ethanol injection in a case of hepatocellular carcinoma. <i>Acta Hepatologica Japonica</i> , 2011, 52, 671-678.	0.0	1
137	Analysis of treatment outcome for lens culinaris agglutinin-reactive alpha-fetoprotein-positive hepatocellular carcinoma in relation to post-treatment disappearance of protein. <i>Journal of Microwave Surgery</i> , 2011, 29, 109-113.	0.3	0
138	A Case of Hepatocellular Carcinoma with Multiple Extrahepatic Metastases at Different Times. <i>Nihon Gekakei Rengo Gakkaishi (Journal of Japanese College of Surgeons)</i> , 2011, 36, 981-986.	0.0	1
139	Spontaneous regression of multiple lung metastases of hepatocellular carcinoma: report of two cases. <i>Acta Hepatologica Japonica</i> , 2012, 53, 417-424.	0.0	0
140	Current Status of Hepatocellular Carcinoma Treatment in Japan. <i>Clinical Drug Investigation</i> , 2012, 32, 3-13.	1.1	10
141	A therapeutic effective case of bronchial arterial infusion of fine-powder cisplatin (IA-call [^] [^] reg;) for pulmonary metastases originated from hepatocellular carcinoma. <i>Acta Hepatologica Japonica</i> , 2013, 54, 19-26.	0.0	1
142	Complete response induced by half dose of sorafenib administration in advanced hepatocellular carcinoma with peritoneal dissemination. <i>Acta Hepatologica Japonica</i> , 2014, 55, 100-105.	0.0	1
143	A Case of a Gallbladder Infarction after Transcatheter Arterial Chemoembolization, Recovered with Only Medical Treatment. <i>Soonchunhyang Medical Science</i> , 2015, 21, 184-187.	0.0	0
144	Combination with Hyperthermia and Chemotherapy: Liver Cancer. , 2016, , 261-274.		1
145	Current HCC Staging Systems: Their Uses and Limitations. , 2016, , 425-442.		4
146	Comparison of the Local Control Effects of Microballoon-Occluded Transarterial Chemoembolization (TACE) Using Miriplatin and Using Epirubicin for Hepatocellular Carcinoma: A Retrospective Study of 62 Cases. <i>Interventional Radiology</i> , 2017, 2, 64-73.	0.2	1

#	ARTICLE	IF	CITATIONS
147	Rate and Predictive Factors for Sustained Complete Response after Selective Transarterial Chemoembolization (TACE) in Patients with Hepatocellular Carcinoma. <i>Asian Pacific Journal of Cancer Prevention</i> , 2018, 19, 3545-3550.	0.5	18
149	Recent progress in treatment of hepatocellular carcinoma. <i>American Journal of Cancer Research</i> , 2020, 10, 2993-3036.	1.4	55
150	Treatment and the prognosis of hepatocellular carcinoma in Asia. <i>Liver International</i> , 2022, 42, 2042-2054.	1.9	49
151	Diagnostic Performance of Extrahepatic Protein Induced by Vitamin K Absence in the Hepatocellular Carcinoma: A Systematic Review and Meta-Analysis. <i>Diagnostics</i> , 2023, 13, 816.	1.3	3